KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $58.5 million.

  • NovoCure's Cost of Revenue fell 214.61% to $58.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.8 million, marking a year-over-year increase of 345.48%. This contributed to the annual value of $239.1 million for FY2024, which is 540.28% up from last year.
  • NovoCure's Cost of Revenue amounted to $58.5 million in Q3 2025, which was down 214.61% from $57.1 million recorded in Q2 2025.
  • NovoCure's Cost of Revenue's 5-year high stood at $67.4 million during Q4 2024, with a 5-year trough of $31.4 million in Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $55.2 million (2024), whereas its average is $49.9 million.
  • As far as peak fluctuations go, NovoCure's Cost of Revenue surged by 4002.66% in 2023, and later tumbled by 320.07% in 2024.
  • NovoCure's Cost of Revenue (Quarter) stood at $39.0 million in 2021, then increased by 27.31% to $49.6 million in 2022, then grew by 19.26% to $59.2 million in 2023, then grew by 13.89% to $67.4 million in 2024, then fell by 13.15% to $58.5 million in 2025.
  • Its Cost of Revenue stands at $58.5 million for Q3 2025, versus $57.1 million for Q2 2025 and $55.8 million for Q1 2025.